Mumbai, July 16 -- Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee(R) (insulin glargine) at its insulin manufacturing facility in Malaysia.

Supplies to Europe from this line are expected to begin from Q2FY27.

Published by HT Digital Content Services with permission from Capital Market....